Integration of CD4+ T cells and molecular subtype predicts benefit from PD‐L1 blockade in muscle‐invasive bladder cancer
Liu G, Jin K, Liu Z, Su X, Xu Z, Li B, Xu J, Liu H, Chang Y, Zhu Y, Xu L, Wang Z, Wang Y, Zhang W. Integration of CD4+ T cells and molecular subtype predicts benefit from PD‐L1 blockade in muscle‐invasive bladder cancer. Cancer Science 2024, 115: 1306-1316. PMID: 38402640, PMCID: PMC11007017, DOI: 10.1111/cas.16119.Peer-Reviewed Original ResearchMuscle-invasive bladder cancerImmune checkpoint blockadeCombination of immune checkpoint blockadeCD4<sup>+</sup> T cellsFibroblast growth factor receptor 3T cellsZhongshan HospitalMolecular subtypesBladder cancerMuscle-invasive bladder cancer patientsResponses to FGFR inhibitorsCD4+ T cellsPD-L1 blockadeImmune suppressive microenvironmentTransforming growth factor-bGrowth factor BIMvigor210 cohortCheckpoint blockadePD-L1Clinical responseSuppressive microenvironmentImmune microenvironmentImmunotherapeutic responseChemotherapeutic responseClinical outcomesIntegrating molecular subtype and CD8+ T cells infiltration to predict treatment response and survival in muscle-invasive bladder cancer
Li B, Jin K, Liu Z, Su X, Xu Z, Liu G, Xu J, Liu H, Chang Y, Wang Y, Zhu Y, Wang Z, Xu L, Zhang W. Integrating molecular subtype and CD8+ T cells infiltration to predict treatment response and survival in muscle-invasive bladder cancer. Cancer Immunology, Immunotherapy 2024, 73: 66. PMID: 38430246, PMCID: PMC10908619, DOI: 10.1007/s00262-024-03651-3.Peer-Reviewed Original ResearchConceptsMuscle-invasive bladder cancerCD8+ T cell infiltrationT cell infiltrationMolecular subtypesBladder cancerEfficacy of antitumor responseElevated tumor mutation burdenPositive response to immunotherapyCD8+ T cellsPD-L1 expressionResponse to immunotherapyTumor mutational burdenResponse to chemotherapyOverall survival outcomesSubtype-specific treatmentAntitumor responsePD-L1Intrinsic subtypesMutational burdenZhongshan HospitalSurvival outcomesT cellsTreatment responseResultsAmong patientsCancer Genome Atlas